The worldwide COVID-19 pandemic has led to more than 15 million deaths. Many cardiovascular risk factors (eg, obesity or diabetes) are associated with an increased risk of adverse outcomes in COVID-19; however, it has been suggested that medications used to treat cardiometabolic conditions may have protective effects for patients with COVID-19.
